Study identification

PURI

https://redirect.ema.europa.eu/resource/48476

EU PAS number

EUPAS43721

Study ID

48476

Official title and acronym

Twenty years of COPD primary care: Patterns of management of high-risk COPD and opportunities for optimising care in the United Kingdom 2000-2019: Study Protocol (CONQUEST UK Opportunity Analysis)

DARWIN EU® study

No

Study countries

United Kingdom

Study description

The main aim for this “Opportunity Analysis” is to assess the management of patients with modifiable high-risk COPD over 20 years in UK primary care and describe opportunities for treatment optimisation in line with the Quality Standards, over this period. The analysis will focus specifically on patients in whom this risk is modifiable, i.e. whose treatment can be optimised as described above. The objectives per quality standards are: 1. Assess whether undiagnosed patients who potentially have modifiable high-risk COPD are actively and promptly identified in UK primary care. 2. Assess whether modifiable high-risk patients with newly diagnosed COPD receive a proper assessment and quantification of future risk of exacerbations and cardiac events within 12 months of diagnosis. 3. Assess whether pharmaceutical and non-pharmacological therapy is provided to patients with modifiable high-risk COPD within 12 months of meeting criteria for modifiable high-risk COPD. 4. Assess whether modifiable high-risk patients diagnosed with COPD are followed up appropriately over a 12m period following baseline assessment 5. (Exploratory) To compare the management of COPD patients in different socio-demographic categories (including age and gender), using key selected indicators from each objective above (1-4). These objectives will be applied:- i) To all patients fitting criteria in years 2014-2019 combined, to assess current management, and ii) Separately in each year between 2000 and 2019 to assess changing trends in COPD management over time.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

David Price

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Non-for-profit organisation (e.g. charity)
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, Observational and Pragmatic Research Institute Pte Ltd
Study protocol
Initial protocol

OPCG-1801_CONQUESTUK Opportunity Analysis Document_V0.9.4_20210520 FINAL

English (825.01 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable